Marijuana users found to have 16% lower fasting insulin levels than non-users
Marijuana use has been associated with lower fasting insulin levels
<p> </p> <div> People who smoke marijuana have been found to have 16 per cent lower fasting insulin levels than non-users, according to research published in The American Journal of Medicine.</div> <div> </div> <div> In light of the findings, professor of medicine at the University of Arizona College of Medicine, Tucson, Joseph Albert, called for more basic and clinical research into the short and long-term effects of marijuana in a variety of clinical settings, including cancer and diabetes. </div> <div> </div> <div> Data from 4,657 patients who completed a drug questionnaire was used to inform the research. Some 579 were current marijuana users, while 1,975 had used it in the past. </div> <div> </div> <div> Those who reported using marijuana in the past month had lower levels of fasting insulin and HOMA-IR. The link was weaker in candidates that reported using marijuana at least once, but not in the past 30 days. </div> <div> </div> <div> Professor Albert commented: "These are indeed remarkable observations that are supported, as the authors note, by basic science experiments that came to similar conclusions."</div> <div> </div> <div> Previous studies have shown that while marijuana users tend to take in more calories, they often have lower body mass indexes and smaller waist circumferences. </div>
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance